All In Biotech

Drug Trial Radar · NCT07781293

Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy

Evaluating the Efficacy and Safety of Lurasidone as Adjunctive Therapy in Adult Patients Diagnosed With Major Depressive Disorder Who Have an Inadequate Response to Antidepressant Monotherapy: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 364 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

364

Planned (sponsor's estimate)

Start

Sep 28, 2026

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Bukwang PharmaceuticalIndustry
Sponsor type
Industry
First posted
Aug 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of lurasidone as adjunctive therapy in adult patients with major depressive disorder (MDD) who show an inadequate response to antidepressant monotherapy. Eligible participants will continue their background antidepressant treatment and be randomized to receive either lurasidone (20, 40, or 60 mg/day) or placebo for 8 weeks. The primary endpoint is the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 8. Secondary endpoints include response and remission rates, changes in Clinical Global Impression-Severity (CGI-S), 17-item Hamilton Depression Rating Scale (HAM-D17), Hamilton Anxiety Rating Scale (HAM-A), and Sheehan Disability Scale (SDS) scores. Safety assessments will include adverse events, laboratory tests, electrocardiograms (ECGs), vital signs, and suicidality monitoring Columbia-Suicide Severity Rating Scale (C-SSRS).

Conditions

  • Major Depressive Disorder (MDD)
  • Major Depressive Disorder With Psychotic Features

Interventions

  • LurasidoneDrug

    Lurasidone

  • PlaceboDrug

    Placebo

  • Background Antidepressant TherapyDrug

    Background Antidepressant treatment (ADT)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale Total Score at Week 8Time frame: Baseline to Week 8

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.